Ozanimod Cas:1306760-87-1

We are Ozanimod CAS:1306760-87-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Description:

Product Name: Ozanimod CAS NO: 1306760-87-1

 

Synonyms:

RPC-1063;

(S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile;

Benzonitrile,5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)-;

 

Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.0%

Density: 1.30±0.1 g/cm3 (Predicted)

Boiling Point: 648.3±65.0℃ (Predicted)

PKa: 14.73±0.10 (Predicted)

Flash Point: 345.9±34.3℃

Vapor Pressure: 0.0±2.0 mmHg at 25℃

Index of Refraction: 1.635

 

Ozamode is a potential phossphynosin-1 receptor agonist for the treatment of multiple sclerosis (MS) and ulcerative colitis that induces Chemicalbook isolation of peripheral blood lymphocytes, reducing the number of activated lymphocytes circulating to the gastrointestinal tract. According to detailed results from the Touchstone Consolidation Phase, patients treated with Ozamod had a significantly higher clinical remission target or sclera rate at week 32 than those treated with placebo. Ozamod is used to treat multiple sclerosis, ulcerative colitis and Crohn”s disease. Among them, multiple sclerosis and ulcerative colitis not only have a long course of disease, high incidence, and need years of medication. Visible, Ozamod market capacity is huge, the prospect is considerable.

 

If you are interested in our products or have any questions, please feel free to contact us!

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

Related Products:Glycine, N-benzoylglycyl-L-alanyl-L-alanyl-L-lysyl-L-alanyl- manufacturer | 2-isobutyryl-3,6,6-trimethyl-2-cyclohexenone supplier | 4-(dimethylamino)-5-methyl-1,5-diphenyl-1,5-dihydro-2H-imidazol-2-one producer.